BenevolentAI

BenevolentAI is a leader in applying advanced AI to accelerate biopharma drug discovery, blending science and technology with a focus on finding solutions for complex diseases. The company has built an AI-enabled drug discovery engine designed to drive a revolution in drug discovery. At the core of their approach is the Benevolent Platform™, which unlocks the power of a vast biomedical data landscape to provide a multidimensional representation of human biology across all diseases. This platform empowers both biopharmaceutical companies and internal scientists to harness the full potential of data and AI to accelerate scientific advances. BenevolentAI offers end-to-end drug discovery services and has established industry-leading collaborations, including a multi-year partnership with AstraZeneca focusing on chronic kidney disease and idiopathic pulmonary fibrosis. The company is also progressing its own preclinical and clinical development pipeline, with its lead asset, BEN-8744 for ulcerative colitis, currently in Phase I clinical trials. BenevolentAI recently entered a new strategic collaboration with Merck to identify and develop innovative compounds in oncology, neurology, and immunology. The company's approach aims to improve the probability of clinical success and deliver life-changing treatments to patients by leveraging AI throughout the drug discovery and development process.